Aurobindo Pharma Limited - Laporan Laba Rugi (TTM)

Aurobindo Pharma Limited
IN ˙ BSE
₹ 1,212.10 ↓ -17.30 (-1.41%)
2025-05-02
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Aurobindo Pharma Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 244,617 249,316 247,746 245,518 240,103 236,476 234,555 239,894 237,869 241,918 248,554 254,700 269,500 278,947 290,019 297,184 302,950 309,218 317,237 320,248
Change (%) 1.92 -0.63 -0.90 -2.21 -1.51 -0.81 2.28 -0.84 1.70 2.74 2.47 5.81 3.51 3.97 2.47 1.94 2.07 2.59 0.95
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 102,848 102,921 101,898 101,486 101,385 103,105 104,499 109,704 110,328 111,961 116,417 119,097 125,784 128,214 129,857 129,037 128,772 130,420 134,839 131,928
Change (%) 0.07 -0.99 -0.40 -0.10 1.70 1.35 4.98 0.57 1.48 3.98 2.30 5.61 1.93 1.28 -0.63 -0.21 1.28 3.39 -2.16
% of Revenue 42.04 41.28 41.13 41.34 42.23 43.60 44.55 45.73 46.38 46.28 46.84 46.76 46.67 45.96 44.78 43.42 42.51 42.18 42.50 41.20
Gross Operating Profit 141,768 146,395 145,848 144,032 138,718 133,372 130,056 130,191 127,541 129,957 132,137 135,603 143,716 150,733 160,162 168,147 174,178 178,797 182,399 188,321
Change (%) 3.26 -0.37 -1.25 -3.69 -3.85 -2.49 0.10 -2.04 1.89 1.68 2.62 5.98 4.88 6.26 4.99 3.59 2.65 2.01 3.25
% of Revenue 57.96 58.72 58.87 58.66 57.77 56.40 55.45 54.27 53.62 53.72 53.16 53.24 53.33 54.04 55.22 56.58 57.49 57.82 57.50 58.80
SG&A 35,761 36,591 36,576 36,395 35,864 35,746 35,751 35,854 35,950 36,478 36,560 37,278 38,143 38,823 40,434 41,633 43,178 44,597 45,470 46,325
Change (%) 2.32 -0.04 -0.49 -1.46 -0.33 0.01 0.29 0.27 1.47 0.23 1.96 2.32 1.78 4.15 2.97 3.71 3.29 1.96 1.88
% of Revenue 14.62 14.68 14.76 14.82 14.94 15.12 15.24 14.95 15.11 15.08 14.71 14.64 14.15 13.92 13.94 14.01 14.25 14.42 14.33 14.47
R&D
Change (%)
% of Revenue
OpEx 201,740 205,097 203,210 201,704 199,118 199,240 201,491 209,275 210,786 215,678 223,435 227,789 238,120 242,117 246,104 249,363 253,148 259,103 267,366 270,865
Change (%) 1.66 -0.92 -0.74 -1.28 0.06 1.13 3.86 0.72 2.32 3.60 1.95 4.54 1.68 1.65 1.32 1.52 2.35 3.19 1.31
% of Revenue 82.47 82.26 82.02 82.15 82.93 84.25 85.90 87.24 88.61 89.15 89.89 89.43 88.36 86.80 84.86 83.91 83.56 83.79 84.28 84.58
Operating Income 42,877 44,219 44,536 43,814 40,985 37,236 33,064 30,620 27,082 26,240 25,119 26,910 31,380 36,830 43,915 47,821 49,802 50,115 49,871 49,384
Change (%) 3.13 0.72 -1.62 -6.46 -9.15 -11.20 -7.39 -11.55 -3.11 -4.27 7.13 16.61 17.37 19.24 8.89 4.14 0.63 -0.49 -0.98
% of Revenue 17.53 17.74 17.98 17.85 17.07 15.75 14.10 12.76 11.39 10.85 10.11 10.57 11.64 13.20 15.14 16.09 16.44 16.21 15.72 15.42
Interest Expense -2,330 -2,153 -596 -514 -461 -427 -368 -386 -535 -823 -1,290 -1,709 -2,138 -2,444 -2,681 -3,226 -3,671 -4,100 -4,404 -4,440
Change (%) -7.56 -72.34 -13.75 -10.30 -7.29 -13.78 4.75 38.53 53.93 56.70 32.51 25.10 14.31 9.72 20.33 13.80 11.69 7.40 0.81
% of Revenue -0.95 -0.86 -0.24 -0.21 -0.19 -0.18 -0.16 -0.16 -0.22 -0.34 -0.52 -0.67 -0.79 -0.88 -0.92 -1.09 -1.21 -1.33 -1.39 -1.39
Net Income 31,421 53,831 53,348 53,218 52,109 28,676 26,482 23,987 21,112 19,977 19,275 19,777 23,254 27,705 31,730 35,214 35,816 34,912 34,859 33,914
Change (%) 71.32 -0.90 -0.25 -2.08 -44.97 -7.65 -9.42 -11.99 -5.38 -3.51 2.60 17.58 19.14 14.53 10.98 1.71 -2.53 -0.15 -2.71
% of Revenue 12.84 21.59 21.53 21.68 21.70 12.13 11.29 10.00 8.88 8.26 7.75 7.76 8.63 9.93 10.94 11.85 11.82 11.29 10.99 10.59

Source: Capital IQ

Other Listings
IN:AUROPHARMA ₹ 1,044.40
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista